These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271 [TBL] [Abstract][Full Text] [Related]
7. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800 [TBL] [Abstract][Full Text] [Related]
9. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas]. Miyagami M; Nakamura S No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195 [TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas]. Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157 [TBL] [Abstract][Full Text] [Related]
12. CD147 expression in pituitary adenomas and its significance for clinical outcome. Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119 [TBL] [Abstract][Full Text] [Related]
13. Clinical features and growth fractions of pituitary adenomas. Yonezawa K; Tamaki N; Kokunai T Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815 [TBL] [Abstract][Full Text] [Related]
14. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Pegolo G; Buckwalter JG; Weiss MH; Hinton DR Acta Cytol; 1995; 39(5):887-92. PubMed ID: 7571965 [TBL] [Abstract][Full Text] [Related]
15. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805 [TBL] [Abstract][Full Text] [Related]
16. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]